Artificial intelligence-calculated hepatorenal index for quantitative evaluation of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease
Pál N. Kaposi-Novák, Budapest / Hungary
Author Block: Z. Zsombor, A. D. Rónaszéki, B. Csongrády, R. Stollmayer, B. K. Budai, V. Bérczi, P. Maurovich-Horvat, K. Hagymási, P. N. Kaposi-Novák; Budapest/HUPurpose: The goal of our study was to evaluate artificial intelligence-calculated hepatorenal index (AI-HRI) as a diagnostic method for hepatic steatosis.Methods or Background: We prospectively enrolled 103 patients with clinically suspected metabolic dysfunction-associated steatotic liver disease (MASLD). All patients had a quantitative ultrasound (QUS), including AI-HRI, ultrasound attenuation coefficient (AC), and ultrasound backscatter-distribution coefficient (SC) measurements. The ultrasonographic fatty liver indicator (US-FLI) score was also calculated. The magnetic resonance imaging fat fraction (MRI-PDFF) was the reference to classify patients into four grades of steatosis: none <5%, mild 5-10%, moderate 10-20%, and severe ≥20%. We determined the agreement between AI-HRI by two examiners using the intraclass correlation coefficient (ICC) of 68 cases.Results or Findings: The AI-HRI was significantly different between groups without (- 480 ±0.607, p<0.003) and with mild steatosis (2.155 ±0.776), as well as between mild and moderate steatosis (2.777 ±0.923, p<0.018). AI-HRI showed a moderate correlation with AC (Spearman's r=0.597), SC (rs=0.473), US-FLI (r=0.5), and MRI-PDFF (r=0.528). The agreement in AI-HRI was good between the two examiners (ICC=0.635, 95% confidence interval (CI)=0.411–0.774, p<0.001). The AI-HRI could detect mild steatosis (AUC=0.758, 95% CI=0.621–0.894) with fair and moderate/severe steatosis (AUC=0.803, 95% CI=0.721–0.885) with good accuracy. However, the performance of AI-HRI was not significantly different (p<0.578) between the two diagnostic tasks.
Conclusion: AI-HRI is an efficient, reproducible, and accurate QUS method to diagnose mild and moderate hepatic steatosis.Limitations: This is a single-centre study with a limited number of patients.Funding for this study: No funding was received for this study.Has your study been approved by an ethics committee? YesEthics committee - additional information: This study was approved by the Regional and Institutional Science and Research Ethics Committee at Semmelweis University (Protocol number: SE RKEB 140/2020, 16-07-2020).